Advancing Precision Cancer Treatment Through Liquid Biopsy and Drug Development
Guardant Health and Nuvalent have entered a strategic partnership to integrate liquid biopsy diagnostics with targeted kinase inhibitors. This collaboration aims to accelerate precision oncology by using blood-based genomic profiling ... Read More